Retrospective observational study of the administration of Jusvinza, for the management of COVID-19 at the Hospital Dr. Luis Diaz Soto”.

Not Applicable

• Conditions: Systemic inflammation by Covid-19; COVID-19; SARS-CoV-2; Coronavirus Infections; Coronaviridae Infections; Severe Acute Respiratory Syndrome; SARS Virus; Betacoronavirus; Respiratory Tract Diseases

• Registration Number: RPCEC00000394
• Lead Sponsor: Center for Genetic Engineering and Biotechnology (CIGB)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-10-29
• Study Completion: 2021-11-30
• Results First Posted: 2022-01-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 348

Inclusion Criteria

1. Patients older than 19 years.
2. SARS-CoV-2 positive patients in moderate, severe or critical conditions, who have been indicated for treatment with Jusvinza, in the period between March 20 and September 6, 2021.

Exclusion Criteria

Not applicable

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Percentage of high risk patients recovered. Measurement time: 7 days after treatment<br>2. Percentage of seriously ill patients recovered. Measurement time: 10 days after treatment<br>3. Percentage of critically ill patients recovered. Measurement time: 15 days after treatment<br>